CN106380459A - Lipid-lowering flavonoid - Google Patents
Lipid-lowering flavonoid Download PDFInfo
- Publication number
- CN106380459A CN106380459A CN201610744109.5A CN201610744109A CN106380459A CN 106380459 A CN106380459 A CN 106380459A CN 201610744109 A CN201610744109 A CN 201610744109A CN 106380459 A CN106380459 A CN 106380459A
- Authority
- CN
- China
- Prior art keywords
- cooh
- composition
- anhydroicartin
- flavone compound
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/74—Benzo[b]pyrans, hydrogenated in the carbocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention discloses a lipid-lowering flavonoid. The flavonoid is commercially available, or is a monomer or a pharmaceutical salt thereof prepared according to an existing method. The pharmaceutical salt comprises a basic salt, such as sodium salt, potassium salt and calcium salt. The lipid-lowering flavonoid can be used for preparing drugs, health-care products, or functional food.
Description
Technical field
The invention belongs to natural medicine field, disclose a kind of compound of lipid-loweringing, specifically disclose a kind of Huang of lipid-loweringing
Ketone compounds.
Background technology
Barrenwort (Epimedium brevicornum Maxim) is jamaicin section plant barrenwort, Epimedium sagittatum, soft
Hair barrenwort or the dried leaf of korean epimedium herb.Barrenwort is just loaded in《Sheng Nong's herbal classic》, " the main impotence of barrenwort described in book
Hinder absolutely, pains in the penis, diuresis, beneficial gas power, strong will ".Barrenwort is traditional help class Chinese medicine, quilt《Chinese Pharmacopoeia》Recorded,
Main product, in Shaanxi, Liaoning, Shandong, Sichuan and other places, has the effects such as kidney-replenishing, strengthening the bones and muscles, wines used as antirheumatic, to impotence, seminal emission, muscles and bones
Aching and limp, numb in every limb contraction, climacteric hypertension, cardiovascular and cerebrovascular disease and improve immunity of organisms, the aspect such as antitumor has
Significant curative effect.Epimedium active constituent and its extract have extensive physiologically active, and its research range is concentrated mainly on
To the aspect such as osseous system, immunological regulation and anti-aging, reproductive system, cardiovascular system.
The flavone compounds such as anhydroicartin (Anhydroicaritin) are the main of traditional traditional tonic medicine barrenwort
One of active monomer component.Recent study finds anhydroicartin to nervous system, internal system, cardiovascular system
System, immune system all show performance pharmacological action to various diseases.So far there are no relevant anhydroicartin and its derivative fall
The report of fat.
Content of the invention
The invention discloses a kind of flavone compound of lipid-loweringing, structural formula is as follows：
The invention discloses a kind of flavone compound of lipid-loweringing, in Formula one
R1=H ,-CH2CH3、CH3、rha、rha-glc、rha-xyl、rha-rha、
-CH2CH2CH=CH2、-CH2CH2OCH3、-CH2CH2Br、
-CH2CH=C (CH3)、-H2PO4、-HSO4、
-CH2CH2OH、-CH2CH=CH2、-CH2COOH、-COO、
-COCH3、-CH(COOH)CH3、-CH2OCH3、
-CH2CH2CH2OH、-CH2CH2NH2、
-CH2CH=C (CH3)2、-CH2CH2CH2COOH、
-CH2COOCH2CH3、-(CH2)2O(CH2)2O(CH2)2OH、
-CH2CH=CHCOOH ,-(CH2)2COCH2、
-CH(COOH)2、-COOC(CH)3,-COCH=C (CH3)2、
-CH(CH3)COOCH2CH3、-CH(COOH)2、
-(CH2)3COOCH2CH3、-CH2CHN(CH3)CH3
-CH2COOH、-(CH2)2OCH3、-(CH2)2OCH3、-SO2CH3
-CH2CH=CHCOOCH2CH3、-CO(CH2)2COOH
-CH2H2PO3、CH(COOH)CH3、-(CH2)2COOH
-CH2OCH3、-(CH2)2N(CH3)2、-CH2CH=CHCOOH
-COCH2CH2CH3
R2=H, glc, CH3、-CH2CH3、-CH2CH2OH、
-CH2CH=CH2、-CH2Ph、
-COCH3、-COOH、-CH(COOH)CH3、-CH2OCH3、
-CH2CH2CH2OH、-CH2CH2NH2、
-CH2CH=C (CH3)2、-(CH2)3COOH、
-CH2COOCH2CH3、-CH2CH=CHCOOH,
-CH(CH3)COOCH2CH3、-(CH2)2COOCH2CH3
-CH2COOH、-(CH2)2Ph、-SO3CH3、
-CH2CH=CHCOOCH2CH3、-CH(COOH)CH3
-(CH2)2COOH、-CH2Ph、-(CH2)3COOH
-CH2CH=CHCOOH ,-COCH2CH2CH3、
-CH(COOCH2CH3)
R3=H ,-CH3、-COCH3、-CH2CH3、-CH2Ph
The invention discloses a kind of flavone compound of formula one is used for preparing the composition of lipid-loweringing；
The invention discloses a kind of flavone compound of formula one is used for the composition that preparation reduces triglycerides；
The invention discloses a kind of flavone compound of formula one is used for the composition that preparation reduces T-CHOL；
The invention discloses a kind of flavone compound of formula one is used for the composition that preparation reduces intracellular triglyceride；
The invention discloses a kind of flavone compound of formula one is used for the composition that preparation reduces intracellular T-CHOL；
The invention discloses a kind of flavone compound of formula one is used for the composition that preparation reduces triglycerides in blood plasma；
The invention discloses a kind of flavone compound of formula one is used for the composition that preparation reduces T-CHOL in blood plasma；
The invention discloses a kind of pharmaceutical salts of the flavone compound of formula one include basic salt such as sodium salt, sylvite and calcium
Salt；
The invention discloses a kind of flavone compound of formula one is made：Medicine, health products or functional food, figuration
Agent or carrier are conventional excipient in pharmacy or field of food or carrier, such as diluent, disintegrant, lubricant etc..
The invention discloses anhydroicartin is used for preparing the composition of lipid-loweringing；
The invention discloses anhydroicartin is used for the composition that preparation reduces triglycerides；
The invention discloses anhydroicartin is used for the composition that preparation reduces T-CHOL；
The invention discloses anhydroicartin is used for the composition that preparation reduces intracellular triglyceride；
The invention discloses anhydroicartin is used for the composition that preparation reduces intracellular T-CHOL；
The invention discloses anhydroicartin is used for the composition that preparation reduces triglycerides in blood plasma；
The invention discloses anhydroicartin is used for the composition that preparation reduces T-CHOL in blood plasma；
The invention discloses anhydroicartin be：Anhydroicartin that is commercially available or pressing known method preparation or its medicine
Use salt；
Wherein anhydroicartin pharmaceutical salts include basic salt such as sodium salt, sylvite and calcium salt；
Composition is made：Medicine, health products or functional food, excipient or carrier are normal in pharmacy or field of food
Excipient or carrier, such as diluent, disintegrant, lubricant etc..
The invention discloses anhydroicartin is used for preparing the composition of lipid-loweringing.
The invention discloses anhydroicartin is used for preparing the composition of lipid-loweringing, the consumption of anhydroicartin is 30-
60mg/kg.
The invention discloses anhydroicartin be used for preparing lipid-loweringing composition, the consumption of anhydroicartin is
30mg/kg.
The invention discloses anhydroicartin be used for preparing lipid-loweringing composition, the consumption of anhydroicartin is
60mg/kg.
The invention discloses anhydroicartin is used for preparing the composition of lipid-loweringing, composition is made：Medicine, health products,
Or functional food, excipient or carrier are conventional excipient in pharmacy or field of food or carrier, such as diluent, disintegration
Agent, lubricant etc..
The invention discloses anhydroicartin is used for preparation treatment or the composition of prevention NASH；
The invention discloses anhydroicartin：For anhydroicartin that is commercially available or pressing known method preparation or its medicine
Use salt；
Wherein anhydroicartin pharmaceutical salts include basic salt such as sodium salt, sylvite and calcium salt；
Composition is made：Medicine, health products or functional food, excipient or carrier are normal in pharmacy or field of food
Excipient or carrier, such as diluent, disintegrant, lubricant etc..
The invention discloses anhydroicartin is used for preparation treatment or the composition of prevention NASH.
The invention discloses anhydroicartin is used for preparation treatment or the composition of prevention NASH, dehydration
The consumption of icariine is 30-60mg/kg.
The invention discloses anhydroicartin is used for preparation treatment or the composition of prevention NASH, dehydration
The consumption of icariine is 30mg/kg.
The invention discloses anhydroicartin is used for treating or prevent the composition of NASH, it is dehydrated excessive sheep
The consumption of leaves of pulse plants element is 60mg/kg.
The invention discloses anhydroicartin is used for preparation treatment or the composition of prevention NASH, system
Become：Medicine, health products or functional food, excipient or carrier are conventional excipient in pharmacy or field of food or carrier,
As diluent, disintegrant, lubricant etc..
The invention discloses icariine is used for preparing the composition of lipid-loweringing；
The invention discloses icariine is used for the composition that preparation reduces triglycerides；
The invention discloses icariine is used for the composition that preparation reduces T-CHOL；
The invention discloses icariine is used for the composition that preparation reduces intracellular triglyceride；
The invention discloses icariine is used for the composition that preparation reduces intracellular T-CHOL；
The invention discloses icariine is used for the composition that preparation reduces triglycerides in blood plasma；
The invention discloses icariine is used for the composition that preparation reduces T-CHOL in blood plasma；
The invention discloses icariine be commercially available or by known method preparation icariine or its pharmaceutical salts；
Wherein icariine pharmaceutical salts include basic salt such as sodium salt, sylvite and calcium salt；
Composition is made：Medicine, health products or functional food, excipient or carrier are normal in pharmacy or field of food
Excipient or carrier, such as diluent, disintegrant, lubricant etc..
The invention discloses icariine is used for preparing the composition of lipid-loweringing.
The invention discloses icariine is used for preparing the composition of lipid-loweringing, composition is made：Medicine, health products or work(
Energy property food, excipient or carrier are conventional excipient in pharmacy or field of food or carrier, such as diluent, disintegrant, profit
Lubrication prescription etc..
The invention discloses different anhydroicartin is used for preparing the composition of lipid-loweringing；
The invention discloses different anhydroicartin is used for the composition that preparation reduces triglycerides；
The invention discloses different anhydroicartin is used for the composition that preparation reduces T-CHOL；
The invention discloses different anhydroicartin is used for the composition that preparation reduces intracellular triglyceride；
The invention discloses different anhydroicartin is used for the composition that preparation reduces intracellular T-CHOL；
The invention discloses different anhydroicartin is used for the composition that preparation reduces triglycerides in blood plasma；
The invention discloses different anhydroicartin is used for the composition that preparation reduces T-CHOL in blood plasma；
The invention discloses different anhydroicartin be commercially available or by known method preparation different anhydroicartin or
Its pharmaceutical salts；
Wherein different anhydroicartin pharmaceutical salts include basic salt such as sodium salt, sylvite and calcium salt；
Composition is made：Medicine, health products or functional food, excipient or carrier are normal in pharmacy or field of food
Excipient or carrier, such as diluent, disintegrant, lubricant etc..
The invention discloses different anhydroicartin is used for preparing the composition of lipid-loweringing.
The invention discloses different anhydroicartin is used for preparing the composition of lipid-loweringing, composition is made：Medicine, health care
Product or functional food, excipient or carrier are conventional excipient in pharmacy or field of food or carrier, and such as diluent collapses
Solution agent, lubricant etc..
The invention discloses icariin is used for the composition that preparation reduces intracellular triglyceride；
The invention discloses icariin is used for the composition that preparation reduces intracellular triglyceride；Composition is made：Medicine
Thing, health products or functional food, excipient or carrier are conventional excipient in pharmacy or field of food or carrier, such as dilute
Release agent, disintegrant, lubricant etc..
The invention discloses icariin II is used for the composition that preparation reduces intracellular triglyceride；
The invention discloses icariin II is used for the composition that preparation reduces intracellular triglyceride；Composition is made：
Medicine, health products or functional food, excipient or carrier are conventional excipient in pharmacy or field of food or carrier, such as
Diluent, disintegrant, lubricant etc..
In order to make it easy to understand, being described in detail to the purposes of the present invention below by the drawings and specific embodiments.Need
Will be it is emphasized that specific embodiments and the drawings be merely to explanation is it is clear that those skilled in the art can be according to herein
Illustrate, the present invention being carried out with various corrections or changing, these are revised and change and also will include within the scope of the invention.
Brief description
Fig. 1. the mouse model changes of weight curve that anhydroicartin induces to high fat
Fig. 2. the mouse model food-intake change curve that anhydroicartin induces to high fat
Fig. 3. the mouse model hepatic pathology section oil red dyeing that anhydroicartin induces to high fat
Fig. 4. the mouse model hepatic pathology section HE dyeing that anhydroicartin induces to high fat
Fig. 5. the mouse model white adipose section HE dyeing that anhydroicartin induces to high fat
Fig. 6. the mouse model brown fat section HE dyeing that anhydroicartin induces to high fat
Become, with AHI structure similar monomer, the aglycon dividing in Fig. 7 barrenwort
Become, with AHI structure similar monomer, the glycosides dividing in Fig. 8 barrenwort
Fig. 9 reduces the activity of cell TC
Figure 10 reduces the activity of cell TG
The data recordation of the present invention is in following form：
The impact of the mouse model food-intake that table 1. anhydroicartin induces to high fat
Content of triglyceride in table 2. excrement
Total cholesterol level in table 3. excrement
Content of triglyceride in table 4. blood plasma
Total cholesterol level in table 5. blood plasma
Table 6. blood plasma middle-high density lipoprotein content
Low-density lipoprotein content in table 7. blood plasma
Table 8. liver weight
Total cholesterol level in table 9. liver
Content of triglyceride in table 10. liver
Specific embodiment
Embodiment 1
In order to study the impact to the mouse model that high fat induces for the anhydroicartin, using C57BL mouse, SPF level, hero
Property, body weight (20 ± 2) g, it is randomly divided into two groups, first group 12, be normal group, give chow diet, remaining mouse (40)
It is divided into 4 groups, give high lipid food (basal feed adds 20% lard, 1.25% cholesterol, 0.5% sodium taurocholate) and freely take the photograph
Food, drinking-water.Give matrix, Lovastatin group (30mg/kg), anhydroicartin low concentration medicine (30mg/kg), dehydration respectively
Icariine high concentration group (60mg/kg).Continuous nursing 6 weeks.
The collocation method of anhydroicartin：With 0.5% CMC-Na solution dissolving.
Observation index：
The ordinary circumstance of a animal
Animal used as test, illumination 12h night 12h, free diet drinking-water, during experiment, animal state is normal.
B observes weekly food-intake, body weight
C excrement triglycerides and total cholesterol level measure
The mouse model food-intake initial data of table 1. high fat induction
As Fig. 1. shown model group is compared normal group body weight and is significantly raised, and prompting modeling is very successful, and anhydroicartin is controlled
After treating 6 weeks, body weight significantly reduces.As Fig. 2. and model group fasting amount shown in table 1. is higher, same prompting modeling success, dehydration is excessive
Sheep leaves of pulse plants extract for treating after 6 weeks food-intake decrease.
Content of triglyceride in table 2. excrement, unit：mM
Compare with high fat group, * P ＜ 0.05, * * P ＜ 0.01, * * * P ＜ 0.001
Total cholesterol level in table 3. excrement, unit：mM
Compare with high fat group, * P ＜ 0.05, * * P ＜ 0.01, * * * P ＜ 0.001
In the excrement of mouse after modeling, T-CHOL (TC), triglycerides (TG) all significantly raise, and have significant system
Difference learned by meter, shows modeling success, is administered TC, TG, the reduction of equal conspicuousness concentration dependent, has significant statistics poor
Different, illustrate that therapeutic effect is notable.
Embodiment 2
The effect to the mouse model that high fat induces for the anhydroicartin
1st, animal used as test and method：
C57BL mouse, SPF level, male, body weight (20 ± 2) g, it is randomly divided into two groups, first group 12, be normal group, give
With chow diet, remaining mouse (40) is divided into four groups of groups, give high lipid food (basal feed adds 20% lard, 1.25%
Cholesterol, 0.5% sodium taurocholate) freely ingest, drink water.Give matrix, Lovastatin group (30mg/kg) respectively, be dehydrated excessive sheep
Leaves of pulse plants element low concentration medicine (30mg/kg), anhydroicartin high concentration group (60mg/kg).After continuous nursing 6 weeks, blood sampling, place
Extremely, take liver organization.
2nd, observation index：
The ordinary circumstance of a animal
Animal used as test is raised in SPF Animal House, illumination 12h night 12h, free diet drinking-water, animal-shaped during experiment
State is normal.
B blood lipids：TC、TG、HDL、LDL
3rd, experimental result：
Result shows：Anhydroicartin can obviously reduce T-CHOL (TC) and triglycerides (TG) in blood plasma, rises
High HDL (HDL-C), reduces after low-density lipoprotein (LDL-C) administration terminates and measures mouse, blood lipid level.Use
T inspection carries out statistical analysis.Result shows, anhydroicartin has improvement result to high fat, has notable significant difference.
Content of triglyceride in table 4. blood plasma, unit：mM
Compare with high fat group, * P ＜ 0.05, * * P ＜ 0.01, * * * P ＜ 0.001
Total cholesterol level in table 5. blood plasma, unit：mM
* P ＜ 0.05, * * P ＜ 0.01, * * * P ＜ 0.001
Table 6. blood plasma middle-high density lipoprotein content, unit：mM
Compare with high fat group, * P ＜ 0.05, * * P ＜ 0.01, * * * P ＜ 0.001
Low-density lipoprotein content in table 7. blood plasma, unit：mM
Compare with high fat group, * P ＜ 0.05, * * P ＜ 0.01, * * * P ＜ 0.001
T-CHOL (TC), triglycerides (TG) in the blood of mouse after modeling, HDL (HDL-C), low close
Degree lipoprotein (LDL-C) all significantly raises, and has significant significant difference, shows modeling success, is administered TC, TG, LDL-C
The reduction of equal conspicuousness concentration dependent, has significant significant difference, illustrates that therapeutic effect is notable.
HDL-C primarily serves the purpose of cholesterol metabolism from blood transportation to liver, is therefore referred to as " good " cholesterol, resists
Atherosclerotic cholesterol, rising modeling group HDL-C due to TC significantly raises, and Lovastatin group and administration group all can show
The content of the rising this " good cholesterol " of work property, illustrates that therapeutic effect is notable.Anhydroicartin can be effectively improved in a word
Hyperlipidemia, reduces TG, TC, LDL-C, raises the content of " good cholesterol " HDL-C.
Embodiment 3
The therapeutic action to NASH for the anhydroicartin
Animal used as test and method：
C57BL mouse, SPF level, male, body weight (20 ± 2) g, it is randomly divided into two groups, first group 12, be normal group, give
With chow diet, remaining mouse (40) gives to give high lipid food respectively, and (basal feed adds 20% lard, and 1.25% courage is solid
Alcohol, 0.5% sodium taurocholate) freely ingest, drink water.It is divided into high fat group, high fat+Lovastatin group (30mg/kg), high fat+dehydration
Icariine low concentration group (30mg/kg), high fat+anhydroicartin high concentration group (60mg/kg).Administration 6 weeks
Observation index：
The ordinary circumstance of a animal
Animal used as test, illumination 12h night 12h, free diet drinking-water, during experiment, animal state is normal.
B blood lipids：TC、TG、HDL、LDL
C pathological examination：HE dyes
D Liver lipids accumulate index of correlation：TC in TG in liver weight, liver, liver
Administration measures mouse, blood lipid level after terminating.Carry out statistical analysis using t inspection.
2. interpretation of result
TC in the blood of mouse after modeling, TG, HDL-C, LDL-C all significantly raise, and have significant significant difference,
Show modeling success, be administered TC, the reduction of TG, LDL-C equal conspicuousness concentration dependent, there is significant significant difference, say
Mingzhi's therapeutic effect is notable.
HDL-C primarily serves the purpose of cholesterol metabolism from blood transportation to liver, is therefore referred to as " good " cholesterol, resists
Atherosclerotic cholesterol, rising modeling group HDL-C due to TC significantly raises, and Lovastatin group and administration group all can show
The content of the rising this " good cholesterol " of work property, illustrates that therapeutic effect is notable.
In data display liver, the result of triglycerides and cholesterol level shows, triglycerides liter in liver after modeling
Height, cholesterol about raises, and illustrates that in liver, triglycerides Cholesterol Accumulation is notable, gives Lovastatin and anhydroicartin
Return to normal.In sum, the modeling of data display NASH is set up, and after administration, therapeutic effect is notable, has
Significant difference.
Table 8. liver weight, unit：g
With high fat group, * P ＜ 0.05, * * P ＜ 0.01, * * * P ＜ 0.001
Total cholesterol level in table 9. liver, unit：Mg cholesterol/g fresh liver tissue
With high fat group, * P ＜ 0.05, * * P ＜ 0.01, * * * P ＜ 0.001
Content of triglyceride in table 10. liver, unit：Mg cholesterol/g fresh liver tissue
With high fat group, * P ＜ 0.05, * * P ＜ 0.01, * * * P ＜ 0.001
The preparation of embodiment 4 anhydroicartin
Anhydroicartin tablet
Anhydroicartin 10mg, starch 88g, magnesium stearate 3g
Preparation technology：Take anhydroicartin to cross 100 mesh sieves, plus starch, magnesium stearate mix, and make particle, do
Dry, compressing tablet, obtain final product.
Anhydroicartin capsule
Anhydroicartin 10mg, starch 88g, magnesium stearate 3g
Preparation technology：Take anhydroicartin to cross 100 mesh sieves, plus starch, magnesium stearate mix, and make particle, do
Dry, encapsulated, obtain final product.
Anhydroicartin parenteral solution
Anhydroicartin 47mg, sodium chloride for injection 7mg
Preparation technology：Anhydroicartin is taken to cross 100 mesh sieves, plus the dissolving of 1.9mL water for injection, add sodium chloride for injection
To isotonic, adjust pH value to 7～7.1, filter, refrigerate 24 hours, inject water to ormal weight, filtration, embedding, sterilizing, that is,
?.
Embodiment 6
Cell culture condition：Take the logarithm the HepG2 cell in growth period, planted in 6 orifice plates with 2.5 × 105 density. training
After supporting 24, go to the medium culture 18h. cellular cholesterol containing medicine or DMSO, triglyceride determination kit carries out courage
Sterol and triglyceride determination.
Tested by external Lipid-lowering activities, investigate the external fall with AHI structure similar monomer composition (Fig. 7,8) in barrenwort
Fat activity,
These monomeric compounds are respectively anhydroicartin (AHI), ring anhydroicartin (AICT), the excessive sheep of different dehydration
Leaves of pulse plants element (IAHI), icariine (ICT) and icariin (ICA), icariin I (ICAI), icariin II (ICA II), court
The leaves of pulse plants determines A (EPM A), Epimedin B (EPM B), epimedin C (EPM C).The triglyceride (TG) intracellular to HepG2 and courage are solid
The impact of alcohol (TC) content.Administration concentration：20μM.
Result such as Fig. 9, shown in Figure 10, AHI, ICT, IAHI are respectively provided with significant reduction cell TC, the activity of TG.And AICT
Lipid-lowering activities not notable.
Meanwhile, in glycosides compound, ICA I and ICA II can significantly reduce intracellular TG content, but the impact to TC
Not notable.And other glycosides compounds all do not significantly reduce cell TG, the activity of TC content.Therefore, external Lipid-lowering activities
Experiment shows, in addition to anhydroicartin (AHI), different anhydroicartin (AICT), icariine (IAHI) and its part
Glycosides compound also has Lipid-lowering activities.
Claims (10)
1. a kind of flavone compound of lipid-loweringing, structural formula is as follows：
R1=H ,-CH2CH3、CH3、rha、rha-glc、rha-xyl、rha-rha、
-CH2CH2CH=CH2、-CH2CH2OCH3、-CH2CH2Br、
-CH2CH=C (CH3)、-H2PO4、-HSO4、
-CH2CH2OH、-CH2CH=CH2、-CH2COOH、-COO、
-COCH3、-CH(COOH)CH3、-CH2OCH3、
-CH2CH2CH2OH、-CH2CH2NH2、
-CH2CH=C (CH3)2、-CH2CH2CH2COOH、
-CH2COOCH2CH3、-(CH2)2O(CH2)2O(CH2)2OH、
-CH2CH=CHCOOH ,-(CH2)2COCH2、
-CH(COOH)2、-COOC(CH)3,-COCH=C (CH3)2、
-CH(CH3)COOCH2CH3、-CH(COOH)2、
-(CH2)3COOCH2CH3、-CH2CHN(CH3)CH3
-CH2COOH、-(CH2)2OCH3、-(CH2)2OCH3、-SO2CH3
-CH2CH=CHCOOCH2CH3、-CO(CH2)2COOH
-CH2H2PO3、CH(COOH)CH3、-(CH2)2COOH
-CH2OCH3、-(CH2)2N(CH3)2、-CH2CH=CHCOOH
-COCH2CH2CH3
R2=H, glc, CH3、-CH2CH3、-CH2CH2OH、
-CH2CH=CH2、-CH2Ph、
-COCH3、-COOH、-CH(COOH)CH3、-CH2OCH3、
-CH2CH2CH2OH、-CH2CH2NH2、
-CH2CH=C (CH3)2、-(CH2)3COOH、
-CH2COOCH2CH3、-CH2CH=CHCOOH,
-CH(CH3)COOCH2CH3、-(CH2)2COOCH2CH3
-CH2COOH、-(CH2)2Ph、-SO3CH3、
-CH2CH=CHCOOCH2CH3、-CH(COOH)CH3
-(CH2)2COOH、-CH2Ph、-(CH2)3COOH
-CH2CH=CHCOOH ,-COCH2CH2CH3、
-CH(COOCH2CH3)
R3=H ,-CH3、-COCH3、-CH2CH3、-CH2Ph.
2. a kind of flavone compound according to claim 1 the purposes preparing lipid-lowering composition it is characterised in that：For making
Make preparation for dropping low triglyceride or and, reduce T-CHOL composition.
3. a kind of flavone compound according to claim 1 the purposes preparing lipid-lowering composition it is characterised in that：Dehydration is excessive
Sheep leaves of pulse plants element.
4. a kind of flavone compound according to claim 2 the purposes preparing lipid-lowering composition it is characterised in that：Dehydration is excessive
Sheep leaves of pulse plants element.
5. a kind of flavone compound according to claim 1 or 2 the purposes preparing lipid-lowering composition it is characterised in that：De-
The consumption of water icariine is 30-60mg/kg.
6. a kind of flavone compound according to claim 1 the purposes preparing lipid-lowering composition it is characterised in that：Dehydration is excessive
Sheep leaves of pulse plants element is for the composition of preparation treatment or prevention NASH.
7. according to claim 1 or, a kind of purposes preparing lipid-lowering composition of 2 flavone compound it is characterised in that：
Icariine or, different anhydroicartin.
8. a kind of flavone compound according to claim 1 the purposes preparing lipid-lowering composition it is characterised in that：Barrenwort
Glycosides or, icariin II.
9. a kind of flavone compound according to claim 1 the purposes preparing lipid-lowering composition it is characterised in that：Barrenwort
Glycosides or, icariin II be used for preparation reduce triglycerides composition.
10. a kind of flavone compound according to claim 1 the purposes preparing lipid-lowering composition it is characterised in that：
Flavone compound pharmaceutical salts include basic salt such as sodium salt, sylvite and calcium salt；
Composition is made：Medicine, health products or functional food；
Excipient or carrier are conventional excipient in pharmacy or field of food or carrier.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610744109.5A CN106380459A (en) | 2016-08-25 | 2016-08-25 | Lipid-lowering flavonoid |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610744109.5A CN106380459A (en) | 2016-08-25 | 2016-08-25 | Lipid-lowering flavonoid |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106380459A true CN106380459A (en) | 2017-02-08 |
Family
ID=57917584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610744109.5A Pending CN106380459A (en) | 2016-08-25 | 2016-08-25 | Lipid-lowering flavonoid |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106380459A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112451515A (en) * | 2020-12-04 | 2021-03-09 | 中国科学院广州生物医药与健康研究院 | Human glucagon-like peptide-1receptor activator and application thereof |
| CN116407531A (en) * | 2023-03-17 | 2023-07-11 | 哈尔滨医科大学 | Application of anhydroicaritin in preparation of drugs for inhibiting macrophage iron death to treat atherosclerosis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101284000A (en) * | 2007-04-10 | 2008-10-15 | 殷正丰 | Therapeutic agents for adiposity or fatty liver |
| CN104860958A (en) * | 2015-05-13 | 2015-08-26 | 昆明理工大学 | Two anhydroicaritin crystal forms and preparation method thereof |
| CN104940189A (en) * | 2014-08-31 | 2015-09-30 | 北京罗诺强施医药技术研发中心有限公司 | Composition for treating hyperplasia |
-
2016
- 2016-08-25 CN CN201610744109.5A patent/CN106380459A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101284000A (en) * | 2007-04-10 | 2008-10-15 | 殷正丰 | Therapeutic agents for adiposity or fatty liver |
| CN104940189A (en) * | 2014-08-31 | 2015-09-30 | 北京罗诺强施医药技术研发中心有限公司 | Composition for treating hyperplasia |
| CN104860958A (en) * | 2015-05-13 | 2015-08-26 | 昆明理工大学 | Two anhydroicaritin crystal forms and preparation method thereof |
Non-Patent Citations (9)
| Title |
|---|
| 《INFLAMMATION》 * |
| 《JOURNAL OF ANALYTICAL CHEMISTRY》 * |
| 《YAKUGAKU ZASSHI》 * |
| 《中国动脉硬化杂志》 * |
| 《中药材》 * |
| MANKI KOMATSU等: "Studies on the Constituents of Sophora Species. IV. Constituents of the Root of Sophora angustifolia SIEB. Et ZUCC. (1)", 《YAKUGAKU ZASSHI》 * |
| O.A. SHEVLYAKOVA等: "Identification of Barrenwort Flavonoids by High-Resolution Tandem Mass Spectrometry", 《JOURNAL OF ANALYTICAL CHEMISTRY》 * |
| ZONG-KANG ZHANG等: "Icaritin Inhibits Collagen Degradation-Related Factors and Facilitates Collagen Accumulation in Atherosclerotic Lesions: A Potential Action for Plaque Stabilization", 《INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES》 * |
| 王茜等: "淫羊藿苷对高脂血症大鼠粘附分子基因表达的影响", 《中国动脉硬化杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112451515A (en) * | 2020-12-04 | 2021-03-09 | 中国科学院广州生物医药与健康研究院 | Human glucagon-like peptide-1receptor activator and application thereof |
| WO2022116382A1 (en) * | 2020-12-04 | 2022-06-09 | 中国科学院广州生物医药与健康研究院 | Human glucagon-like peptide-1 receptor activator and application thereof |
| CN116407531A (en) * | 2023-03-17 | 2023-07-11 | 哈尔滨医科大学 | Application of anhydroicaritin in preparation of drugs for inhibiting macrophage iron death to treat atherosclerosis |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102218049B (en) | Anti-ageing medicine or health care food composition and application | |
| CN103446385A (en) | Traditional Chinese medicine preparation for treating diabetic complications | |
| CN104187172A (en) | Functional feed for treating enterogastritis diseases of turtles and preparation method of functional feed | |
| CN103285145B (en) | Pure traditional Chinese medicine preparation for prompting rapid growth of pigs as well as preparation method and application method thereof | |
| CN107998313A (en) | A kind of Chinese medicine ferment for treating goat and preparation method thereof | |
| CN106380459A (en) | Lipid-lowering flavonoid | |
| CN103623046A (en) | Composite playing auxiliary protection role in chemical and alcoholic liver injury, preparation method of composite and application of composite in health-care food | |
| CN104739840A (en) | Novel use of asiatic acid in preparation of drugs for preventing and treating hyperlipidemia and fatty liver | |
| CN103202894B (en) | Chinese herbal medicine feed additive for preventing and curing infectious serositis of duck | |
| WO2021093090A1 (en) | Traditional chinese medicine extract composition having function of regulating depression, preparation method therefor, and chinese medicine preparation | |
| CN101385736A (en) | Use of penoniflorin in preparing medicine for preventing and treating depression and medicine composition thereof | |
| CN104415135B (en) | The purposes of hydroxyl polymethoxyflavone class compound and/or its derivative | |
| CN103520302B (en) | Sea-buckthorn leaf anti-fatigue capsule and preparation method thereof | |
| KR20160094896A (en) | The uses of hydroxyl polymethoxylflavones and/or derivative thereof | |
| CN103083429B (en) | Blood fat-reducing traditional Chinese medicine formula | |
| US10010571B2 (en) | Nutritional supplement for the enhancement of muscle irisin and enhancement of brown fat, metabolic rate, and weight loss, and methods of use thereof | |
| CN106138155A (en) | A kind of compositions preventing and treating hepatitis and application thereof | |
| CN107137416B (en) | A kind of pharmaceutical composition preventing and treating non-small cell lung cancer | |
| CN101912377A (en) | Application of pterostilbene to preparation of medicament for treating cervical cancer | |
| CN104000820B (en) | Application of demethyleneberberine in preparation of drugs for preventing and/or treating ulcerative colitis | |
| CN103494849B (en) | New use of asiatic pennywort herb extract in treatment of hyperlipidaemia and related medicines | |
| CN103623109B (en) | Traditional Chinese medicine composition for treating ischemic cerebrovascular disease and preparation method thereof | |
| CN102617526B (en) | Sesterterpene compounds Hippolide J and its production and use | |
| CN101244041B (en) | Medicament for preventing and treating acute liver damnification and preparation thereof | |
| CN104069149A (en) | Method for processing traditional Chinese medicine decoction piece by using bear gall as matrix |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170208 |
|
| RJ01 | Rejection of invention patent application after publication |